Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05579366 2026-03-03

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

764 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06545331 2026-03-03

DELTA-101

BreastGastrointestinalThoracic

396 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05208762 2026-02-23

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

714 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04348747 2026-02-12

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

23 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07188246 2026-02-11

BRINK

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05082259 2026-02-10

ASTEROID

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

18 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06353997 2026-01-15

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

12 enrolled

Triple Negative Breast Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

495 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

12 enrolled

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05973864 2025-11-17

CAPPA

220 enrolled

Triple Negative Breast Neoplasms

NCT06078384 2025-11-17

ETNA

354 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT06249048 2025-10-29

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

108 enrolled

BreastDermatologic

Melanoma, Triple Negative Breast Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

149 enrolled

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06845319 2025-10-22

NeoCARD

43 enrolled

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05645380 2025-10-07

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05329532 2025-09-17

ModiFY

BreastGenitourinaryHead & Neck

168 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

2,454 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491083 2025-07-25

ComPACT

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05086692 2025-07-09

ABILITY-1

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

115 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06246968 2025-05-21

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

30 enrolled

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06637306 2025-03-26

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

15 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

BreastClassical hematology

23 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

185 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067